Search
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577]
Erythrityl tetranitrate
go.drugbank.com/drugs/DB01613ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)
Carmustine
go.drugbank.com/drugs/DB00262ApprovedInvestigational(From Merck Index, 11th ed) … (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985).
Danaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnThe active constituents are heparan, dermatan and [DB09301] [T28], and they are isolated from the porcine intestinal mucosa [FDA Label]. … While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer.
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L52735] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks, although the ALS Functional Rating Scale–Revised did not … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.
Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SPStanozolol
go.drugbank.com/drugs/DB06718ApprovedVet approvedStanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalSemaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. … [L41335] On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports.
Fomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnFomivirsen is marketed under the trade name Vitravene for intravitreal injection and was the first antisense drug to be approved by the Food and Drug Administration (FDA). … The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated